Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Goldschmidt

Showing results (391-400 of 472) with videos related to

Pageof 48
Sort By:
Journal of the American Veterinary Medical Association|November 15, 1994
Comparison of fibrosarcomas that developed at vaccination sites and at nonvaccination sites in cats: 239 cases (1991-1992)M J Hendrick, F S Shofer, M H Goldschmidt, et al.
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin|September 4, 2004
[Dynamic MRI of the bone marrow for monitoring multiple myeloma during treatment with thalidomide as monotherapy or in combination with CED chemotherapy]K Wasser, T Moehler, K Neben, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2019
Correction: Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III StudyNicholas Thatcher, Jerome H Goldschmidt, Michael Thomas, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|December 19, 2001
No evidence for involvement of alleles of the 825-C/T polymorphism of the G-protein subunit beta 3 in body weight regulationA Hinney, F Geller, T Neupert, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 1997
Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective adjuvant treatment for high-risk primary breast cancerR Haas, H Schmid, U Hahn, et al.
Leukemia|October 3, 2003
High incidence of trisomies 1q, 9q, and 11q in multiple myeloma: results from a comprehensive molecular cytogenetic analysisP Liebisch, C Wendl, A Wellmann, et al.
British Journal of Haematology|March 2, 1999
Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell contentM T Voso, S Hohaus, M Moos, et al.
Der Radiologe|September 28, 2000
[Functional magnetic resonance tomography in the diagnosis and therapy monitoring in multiple myeloma]T M Moehler, H Hawighorst, K Neben, et al.
Veterinary Pathology|February 27, 2020
Biphasic Feline Mammary Carcinomas Including Carcinoma and Malignant MyoepitheliomaAlessandro Sammarco, Giovanni Finesso, Rossella Zanetti, et al.
Leukemia|December 10, 2015
FOXM1 is a therapeutic target for high-risk multiple myelomaC Gu, Y Yang, R Sompallae, et al.
Pageof 48

Showing results (391-400 of 472) with videos related to

Sort By:
Pageof 48
Journal of the American Veterinary Medical Association|November 15, 1994
Comparison of fibrosarcomas that developed at vaccination sites and at nonvaccination sites in cats: 239 cases (1991-1992)M J Hendrick, F S Shofer, M H Goldschmidt, et al.
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin|September 4, 2004
[Dynamic MRI of the bone marrow for monitoring multiple myeloma during treatment with thalidomide as monotherapy or in combination with CED chemotherapy]K Wasser, T Moehler, K Neben, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2019
Correction: Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III StudyNicholas Thatcher, Jerome H Goldschmidt, Michael Thomas, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|December 19, 2001
No evidence for involvement of alleles of the 825-C/T polymorphism of the G-protein subunit beta 3 in body weight regulationA Hinney, F Geller, T Neupert, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 1997
Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective adjuvant treatment for high-risk primary breast cancerR Haas, H Schmid, U Hahn, et al.
Leukemia|October 3, 2003
High incidence of trisomies 1q, 9q, and 11q in multiple myeloma: results from a comprehensive molecular cytogenetic analysisP Liebisch, C Wendl, A Wellmann, et al.
British Journal of Haematology|March 2, 1999
Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell contentM T Voso, S Hohaus, M Moos, et al.
Der Radiologe|September 28, 2000
[Functional magnetic resonance tomography in the diagnosis and therapy monitoring in multiple myeloma]T M Moehler, H Hawighorst, K Neben, et al.
Veterinary Pathology|February 27, 2020
Biphasic Feline Mammary Carcinomas Including Carcinoma and Malignant MyoepitheliomaAlessandro Sammarco, Giovanni Finesso, Rossella Zanetti, et al.
Leukemia|December 10, 2015
FOXM1 is a therapeutic target for high-risk multiple myelomaC Gu, Y Yang, R Sompallae, et al.
Pageof 48